age-related macular degeneration (AMD) 老年性黃斑病變

age-related macular degeneration (AMD) 
繁: 老年性黃斑病變
簡: 老年性黄斑病变

隨着年齡增長，黃斑區逐漸退化，有可能會出現老年性黃斑病變，視力會變得模糊、扭曲，若延誤治療，病變區域會出現疤痕，嚴重甚至有機會失去中央視力。 

老年性黃斑病變4個風險因素 把握治療黃金期  減低中央視力損害（2023年8月18日）。明報健康網，取自https://t.ly/cfw3o

The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), Regeneron said.

US FDA approves higher dose of Regeneron’s eye disease drug Eylea (2023, Aug 19). Reuters. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-regenerons-8-mg-dose-eye-disease-drug-eylea-2023-08-18/